HU9402436D0 - 2,6-method-2h-quinolizin derivative as 5-ht3-receptor antagonist - Google Patents

2,6-method-2h-quinolizin derivative as 5-ht3-receptor antagonist

Info

Publication number
HU9402436D0
HU9402436D0 HU9402436A HU9402436A HU9402436D0 HU 9402436 D0 HU9402436 D0 HU 9402436D0 HU 9402436 A HU9402436 A HU 9402436A HU 9402436 A HU9402436 A HU 9402436A HU 9402436 D0 HU9402436 D0 HU 9402436D0
Authority
HU
Hungary
Prior art keywords
quinolizin
derivative
receptor antagonist
antagonist
receptor
Prior art date
Application number
HU9402436A
Other languages
Hungarian (hu)
Other versions
HU216831B (en
HUT68249A (en
Inventor
Maurice W Gittos
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of HU9402436D0 publication Critical patent/HU9402436D0/en
Publication of HUT68249A publication Critical patent/HUT68249A/en
Publication of HU216831B publication Critical patent/HU216831B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9402436A 1992-02-24 1993-02-03 Process for producing 2,6-methano-2h-quinolizin derivative and pharmaceutical composition containing it HU216831B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24

Publications (3)

Publication Number Publication Date
HU9402436D0 true HU9402436D0 (en) 1994-10-28
HUT68249A HUT68249A (en) 1995-06-28
HU216831B HU216831B (en) 1999-09-28

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9402436A HU216831B (en) 1992-02-24 1993-02-03 Process for producing 2,6-methano-2h-quinolizin derivative and pharmaceutical composition containing it

Country Status (14)

Country Link
EP (1) EP0628043A1 (en)
JP (1) JPH07504192A (en)
KR (1) KR100287933B1 (en)
AU (1) AU675060B2 (en)
CA (1) CA2130563C (en)
FI (1) FI105917B (en)
HU (1) HU216831B (en)
IL (1) IL104821A (en)
MX (1) MX9300948A (en)
NO (1) NO943101L (en)
NZ (1) NZ249346A (en)
TW (1) TW226374B (en)
WO (1) WO1993017019A1 (en)
ZA (1) ZA931146B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048597A1 (en) 1999-02-18 2000-08-24 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
WO2006096626A2 (en) 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE129153T1 (en) * 1988-02-23 1995-11-15 Merrell Dow Pharma USE OF QUINOLICIN AND QUINOLIZINONE DERIVATIVES FOR THE PRODUCTION OF MEDICINAL PRODUCTS.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
AU675060B2 (en) 1997-01-23
HU216831B (en) 1999-09-28
FI943872A (en) 1994-08-23
WO1993017019A1 (en) 1993-09-02
TW226374B (en) 1994-07-11
HUT68249A (en) 1995-06-28
NO943101D0 (en) 1994-08-23
NZ249346A (en) 1995-10-26
IL104821A (en) 1997-01-10
AU3603493A (en) 1993-09-13
JPH07504192A (en) 1995-05-11
CA2130563C (en) 1997-11-11
EP0628043A1 (en) 1994-12-14
ZA931146B (en) 1993-09-14
CA2130563A1 (en) 1993-09-02
MX9300948A (en) 1993-08-01
KR100287933B1 (en) 2001-05-02
FI105917B (en) 2000-10-31
IL104821A0 (en) 1993-06-10
FI943872A0 (en) 1994-08-23
NO943101L (en) 1994-08-23
KR950700297A (en) 1995-01-16

Similar Documents

Publication Publication Date Title
GB9321855D0 (en) 1,4-piperazine derivatives
HU9302460D0 (en) 5/20/4-(1,2-benzisothiazole-3-yl)-1-pierazinyl/ethyl/-6-chlorine-1,3-dihydro-2h-indole-2-one-hydrogen-chloride-mononhydrate
PL307812A1 (en) Substituted thiazolydinone derivatives
HU9202848D0 (en) 1,2-dihydro-2-oxopyridine
EP0569493A4 (en) Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
HK1011350A1 (en) Arylamide derivatives
GB2260135B (en) Substituted 2,6-diaminotoluenes
EP0663839A4 (en) Ibuprofen-h 2? antagonist combinations.
HU9302314D0 (en) 1,4-benzodioxane derivatives
EP0708765A4 (en) Substituted piperazinylcamphor derivatives as oxytocin antagonists
HU9503281D0 (en) Thioindole pyperidinyl derivatives used as antalgics
EP0482206A4 (en) 4,6-o-hydroxyphosphorylglucosamine derivative
GB9320940D0 (en) Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative agents
HU9402436D0 (en) 2,6-method-2h-quinolizin derivative as 5-ht3-receptor antagonist
HU9301651D0 (en) Pyridyl-1,2,5-oxadiazole-carbonamide-2-oxide derivatives
HU908313D0 (en) New 15-nitro-2betha, 3betha-dihydro- and 15-nitro-2betha, 3 betha,6,7-tetrahydro-tabersonine derivatives
HU9300556D0 (en) Substituted phenyl-quinazoline derivatives
GR3033237T3 (en) Quinoline derivatives as leukoriene antagonists.
HU9202296D0 (en) 3,4-dehydro-piperidine derivatives
ZA936048B (en) Novel 3-oxadiazolyl-1,6-napthyridine derivatives
GB9322017D0 (en) 1,4-piperazine derivatives
ZA934972B (en) 21-Chloro-pregnane derivative
GB9320941D0 (en) Substituted hexaydrobenzopyran derivatives as angiotensin 11 antagonists
HU9402902D0 (en) 1,2-dihydro-2-oxo-3-methyl-sulfonyl-aminomethyl-pyridine derivatives
GB2266530B (en) Substituted 1,1,2-triphenylbutenes

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: AVENTISUB II INC., US

Free format text: FORMER OWNER(S): AVENTIS INC., US; MERREL DOW PHARMACEUTICALS INC., US